

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRINCIPAL OPERATING RESULTS ESTIMATE OF JIANGZHONG PHARMACEUTICAL FOR THE YEAR ENDED 31 DECEMBER 2024

On 24 January 2025, Jiangzhong Pharmaceutical released its unaudited preliminary financial information for the year ended 31 December 2024.

Jiangzhong Pharmaceutical Co., Ltd. (江中藥業股份有限公司) (“**Jiangzhong Pharmaceutical**”) is a company incorporated in the People’s Republic of China. The shares of Jiangzhong Pharmaceutical are listed on the Shanghai Stock Exchange. As of the date of this announcement, Jiangzhong Pharmaceutical is owned as to approximately 43.10% equity interest by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) through its non-wholly owned subsidiary, China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (華潤江中製藥集團有限責任公司) (“**CR Jiangzhong Pharmaceutical**”). The Group controls an effective interest of approximately 26.10% of Jiangzhong Pharmaceutical, which is accounted for as a subsidiary of the Company.

On 24 January 2025, Jiangzhong Pharmaceutical released its unaudited preliminary financial information for the year ended 31 December 2024 (the “**Reporting Period**”) (the “**Jiangzhong Pharmaceutical Preliminary Financial Information**”). Set out below are the key financial information of the Jiangzhong Pharmaceutical Preliminary Financial Information:

I. MAJOR FINANCIAL INFORMATION AND INDICATORS FOR THE YEAR OF 2024 (UNAUDITED)

Unit: RMB ten thousand

Item	The Reporting Period	The corresponding period of previous year	The corresponding period of previous year (after retrospective adjustment)	Increase/decrease after retrospective adjustment (%)
Total operating revenue	443,545	439,010	455,321	-2.59
Operating profit	102,642	89,412	91,281	12.45
Total profit	102,374	89,713	91,612	11.75
Net profit attributable to the shareholders of the listed company	78,491	70,829	71,867	9.22
Net profit attributable to the shareholders of the listed company (exclude extraordinary gains or losses)	74,700	70,392	70,392	6.12
Basic earnings per share (<i>RMB</i>)	1.25	1.12	1.14	9.65
Weighted average return on net asset (%)	19.90%	17.75%	17.98%	+1.92 percentage point

Item	As of the end of the Reporting Period	As of the beginning of the Reporting Period	As of the beginning of the Reporting Period (after retrospective adjustment)	Increase/decrease (%)
Total assets	648,914	612,854	640,141	1.37
Equity attributable to the shareholders of the listed company	386,059	383,152	391,363	-1.36
Share capital	62,902	62,936	62,936	-0.05
Net assets per share attributable to the shareholders of the listed company (RMB)	6.14	6.09	6.22	-1.30

Notes:

- (1) The above information for this Reporting Period and the corresponding period of previous year (after retrospective adjustment) are based on information from unaudited consolidated financial statements.
- (2) During the Reporting Period, Jiangzhong Pharmaceutical used its own funds to purchase 51% of the equity of Jiangxi Jiangzhong Chinese Medicine Pieces Co., Ltd. (江西江中中藥飲片有限公司) held by its controlling shareholder, CR Jiangzhong Pharmaceutical (the “**Transaction**”). The Transaction constituted a merger of companies under the same control and Jiangzhong Pharmaceutical had made retrospective adjustments to its FY2023 financial statements.

II. DETAILS OF OPERATING RESULTS AND FINANCIAL POSITIONS

During the Reporting Period, Jiangzhong Pharmaceutical adhered to the strategic guidance of the “14th Five-Year Plan” and focused on the three major business layouts of “strengthening OTC, developing big health and deploying prescription drugs” to enhance core functions and improve core competitiveness. In terms of business, Jiangzhong Pharmaceutical strengthened the construction of OTC product echelons to promote balanced development of regional markets, optimized the business model of health consumer products and improved efficiency through organizational restructuring, explored the development path of prescription drug business and improved business compliance and operation capabilities. At the same time, Jiangzhong Pharmaceutical focused on the bottleneck issues that restrict high-quality development, accelerated the focus on the main business, technological innovation, organizational change and other work and promoted the high-quality development of Jiangzhong Pharmaceutical.

In 2024, Jiangzhong Pharmaceutical achieved operating income of RMB4.435 billion, representing a year-on-year decrease of 2.59% and achieved a net profit attributable to shareholders of the listed company of RMB785 million, representing a year-on-year increase of 9.22%.

The Jiangzhong Pharmaceutical Preliminary Financial Information have been prepared in accordance with the PRC Generally Accepted Accounting Principles and are unaudited. The final audited results for the Reporting Period to be disclosed by Jiangzhong Pharmaceutical in its 2024 annual report shall prevail.

The financial information is limited to Jiangzhong Pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the Jiangzhong Pharmaceutical Audited Annual Financials, please refer to the annual report for the year ended 31 December 2024 to be published by Jiangzhong Pharmaceutical on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By Order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 24 January 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors; and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.